Passer au contenu

/ La recherche


Natural Sciences and Engineering; Health Sciences; Applied Sciences

Davide Brambilla

Laboratory of Pharmaceutical Biotechnology

Professeur adjoint

Faculté de pharmacie

Pavillon Jean Coutu, local 4210

514 343-6111 #0791



MSc Biotechnology (2008), University of Milano-Bicocca, Italy

PhD Pharmaceutical Technology and Biopharmacy (2008-2012), University of Paris-Sud XI, France

Post-doctoral Fellow (2012-2015), Swiss Federal Institute of Technology (ETH) Zurich, Switzerland

Group Leader (2015-2017), Swiss Federal Institute of Technology (ETH) Zurich, Switzerland

MSc Biotechnology (2008), University of Milano-Bicocca, Italy

PhD Pharmaceutical Technology and Biopharmacy (2008-2012), University of Paris-Sud XI, France

Post-doctoral Fellow (2012-2015), Swiss Federal Institute of Technology (ETH) Zurich, Switzerland

Group Leader (2015-2017), Swiss Federal Institute of Technology (ETH) Zurich, Switzerland

Prix et distinctions

Chaire de recherche en Biotherapie de l'Association Canadienne du Medicament Generique et Biosimilaires Canada

ETH Top 5 Inventions 2016 (Spark Award) 

Affiliations et responsabilités

Enseignement et encadrement


Projets de recherche

2018 - 2024

Design of a polymeric microneedles platform for noninvasive and realtime monitoring of physiological parameters

Chercheur principal : Davide Brambilla
Sources de financement : CRSNG/Conseil de recherches en sciences naturelles et génie du Canada (CRSNG)
Programmes de subvention : PVX20965-(RGP) Programme de subvention à la découverte individuelle ou de groupe
2018 - 2021

Le suivi de proBNP a la maison: un changement radical dans le suivi des patients atteints d’insuffisance cardiaque chronique

Chercheur principal : Davide Brambilla
Co-chercheurs : Xavier Banquy , Gregory De Crescenzo
Sources de financement : FRQSC/Fonds de recherche du Québec - Société et culture (FQRSC)
Programmes de subvention : PVXXXXXX-AUDACE (financement partagé entre les fonds de recherche du Québec)
2018 - 2021

Développement de micro-dispositifs pour la quantification hautement sensible et non-invasives des fonctions lymphatiques

Chercheur principal : Davide Brambilla
Sources de financement : FRQNT/Fonds de recherche du Québec - Nature et technologies (FQRNT)
Programmes de subvention : PVXXXXXX-(NC) Établissement de la relève professorale
2018 - 2019

Conception et fabrication de microaiguilles polymériques pour des applications biomédicales

Chercheur principal : Davide Brambilla
Sources de financement : FCI/Fondation canadienne pour l'innovation
Programmes de subvention : PVXXXXXX-Fonds des leaders

Gene editing delivery tools

Chercheur principal : Davide Brambilla

Neutrophil Extracellular Traps targeting

Chercheur principal : Davide Brambilla

Design and manufacturing of microneedles for diagnostic and therapeutic applications

Chercheur principal : Davide Brambilla


Publications et communications


Full list of publications available here

1. D printing of a wearable personalized oral delivery device: a first-in-human study. Liang K., Carmone S., Brambilla D., Leroux JC. Sci. Adv., 2018

2. Pharmacokinetics of Lipid-Drug Conjugates Loaded into Liposomes. Signorell D.R., Luciani P., Brambilla D. & Leroux JC. Eur. J. Pharm. Biopharm., 2018.

3. Antibody-Functionalized Polymer Nanoparticle Leading to Memory Recovery in Alzheimer's Disease-like Transgenic Mouse Model.Carradori D; Balducci C.; Brambilla D.; Re F.; Le Droumaguet B.; Flores O.; Gaudin A.; Mura S.; Forloni G.; Masserini M.; Nicolas J.*; Couvreur P.; Andrieux K.*; Nanomedicine:NBM. 2017, Accepted.

4. Poly(2-oxazoline)-Pterostilbene Block-Copolymer Nanoparticles for Dual-Anticancer Drug Delivery. Romio M., Morgese G., Trachsel L., Babity S., Paradisi C., Brambilla D.*, Benetti EM.* Biomacromolecules. 2018 Accepted *Co-corresponding authors.

5. Drug Discovery, Development and Delivery in Alzheimer's Disease. Brambilla D. Pharm. Res. 2017 Accepted

6. Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas.Signorell, RD; Papachristodoulou, A.; Xiao, J.; Arpagaus B.; Casalini, T.; Grandjean, J.; Thamm, J.; Steiniger, F.; Luciani P.; Brambilla, D.; Werner, B.; Martin, E.; Weller, M.; Roth, P.; Leroux, JC. Int J Pharm. 2017, Accepted.

7. Development of a Modular Ratiometric Fluorescent Probe for the Detection of Extracellular Superoxide. Andina D.; Brambilla D.; Munzinger N.; Frei J.; Zivko C.; Leroux JC. & Luciani P. Chem. Eur. J., 2017, accepted. Highlighted in

8. The effect of settling on cytotoxicity evaluation of SiO2 nanoparticles. Spyrogianni, A.; Sotiriou, GA.; Brambilla, D.; Leroux, JC.; Pratsinis, ES. J. Aerosol Sci., 2017, accepted.

9. Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency. Jong-Ah, K.; Casalini T., Brambilla, D.*; Leroux, JC*. Sci. Rep. 2016. doi:10.1038/srep34297. *Co-corresponding authors.

10. Layer-by-layer coating of solid drug cores: a versatile method to improve stability, control release and tune surface properties.Polomska A.; Leroux JC.*; Brambilla D.* Macromol. Biosci. 2017, 17. *Co-corresponding authors.

11. Microneedles for the noninvasive structural and functional assessment of dermal lymphatic vessels. Brambilla D. Proulx S.T., Marschalkova P., Detmar M., Leroux JC. Small, 2016, DOI: 10.1002/smll.201503093.

12. Permeation of steryl ferulates through an in vitro intestinal barrier model. Zhu, D.; Brambilla, D.; Leroux, JC.; Nyström, L.; Mol. Nutr. Food Res., 2015, 59(6),1182-9.

13. Breakthrough Discoveries in Drug Delivery Technologies: Next 30 years. Brambilla, D.; Luciani, P. & Leroux, JC. J Control Release, 2014, 190, 9-14. Among journal’s most downloaded since publication.

14. Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery. Mura, S.; Zouhiri, F.; Lerondel, S.; Maksimenko, A.; Mougin, J.; Brambilla, D.; Caron, J.; Sliwinski, E.; Le Pape, A.; Desmaele, D.; Couvreur, P. Bioconjugate Chem., 2013, 24 (11), 1840–9.

15. Effect of Nanoparticles Binding Beta-Amyloid Peptide on Nitric Oxide Production by Cultured Endothelial Cells and Macrophages. Orlando, F.; Re, F.; Sesana, S.; Rivolta, I.; Panariti, A.; Brambilla, D.; Nicolas, J.; Couvreur, P.; Andrieux, K.; Masserini, M.; Cazzaniga, E. Int J Nanomed 2013, 8(1), 1335-47.

16. Design, Functionalization Strategies and Biological Applications of Targeted Biodegradable/Biocompatible Polymer-Based Nanoparticles for Drug Delivery. Nicolas, J.; Mura, S.; Brambilla, D.; Mackiewicz, N.; Couvreur, P. Chem Soc Rev 2012. 42, 1147-1235. Highly cited paper (top 1% Web of Science).

17. Versatile and Efficient Targeting from a Single Nanoparticulate Platform: Application to Cancer and Alzheimer’s Disease. Le Droumaguet B.; Nicolas J.;* Brambilla D.; Mura M.; Maksimenko A.; De Kimpe L.; Salvati E.; Zona C.; Airoldi C.; Canovi M.; Gobbi M.; Noiray M.; La Ferla B.; Nicotra F.; Scheper W.; Flores O.; Masserini M.; Andrieux K.; Couvreur P. ACSNano, 2012, 6 (7), 5866-79.

18. PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Towards Engineering of Functional Nanomedicines for Alzheimer's Disease. Brambilla D.; Verpillot R.; Le Droumaguet B.; Taverna M.; Nicolas J.; Kóňa J.; Hashemi S.H.; Lettiero B.; De Kimpe L.; Gobbi M.; Nicolas V.; Scheper W.; Moghimi S.M.; Tvaroška I.; Couvreur P.; Andrieux K. ACSNano, 2012, 6 (7), 5897-08.

19. Colloidal Properties of Biodegradable Nanoparticles Influence Interaction with Amyloid-Beta Peptide. Brambilla, D.; Souguir, H.; Nicolas, J.; Mackiewicz, N.; Verpillot, R.; Le Droumaguet, B.; Taverna, M.; Couvreur, P.; Andrieux, K.; J Biotechnol, 2011, 156, 338.

20. Quantum Dots-Loaded, Pegylated Poly(alkyl cyanoacrylate) Nanoparticles for in Vitro and in Vivo Imaging. Nicolas, J.; Brambilla, D.; Carion, O.; Pons, T.; Maksimovic, I.; Larquet, E.; Le Droumaguet, B.; Andrieux, K.; Dubertret, B.; Couvreur, P.; Soft Matter, 2011, 7, 6187.

21. Nanotechnologies for Alzheimer’s Disease: Therapy, Diagnosis and Safety Issues. Brambilla, D.; Le Droumaguet, B.; Hasheimi, S. H.; Wu, L.-P.; Moghimi, S. M.; Couvreur, P.; Nicolas, J.; Andrieux, K.; Nanomedicine: NBM, 2011, 5, 521.

22. Selegiline-Functionalized, PEGylated Poly(alkyl cyanoacrylate) Nanoparticles to Target the Amyloid- β Peptide. Le Droumaguet, B.; Souguir, H.; Brambilla, D.; Verpillot, R.; Nicolas, J.; Taverna, M.; Couvreur, P.; Andrieux, K.; Int J Pharm, 2011, 416, 453.

23. A New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid-β Peptide. Brambilla, D.; Verpillot, R.; Taverna, M.; De Kimpe, L.; Le Droumaguet, B.; Nicolas, J.; Canovi, M.; Gobbi, M.; Mantegazza, F.; Salmona, M.; Nicolas, V.; Scheper, W.; Couvreur, P.; Andrieux, K.; AnalChem, 2010, 82, 10083.

24. Design of Fluorescently Tagged Poly(alkyl cyanoacrylate) Nanoparticles for Brain Endothelial Cells Imaging. Brambilla, D.; Nicolas, J.; Le Droumaguet, B.; Andrieux, K.; Marsaud, V.; Couraud, P.-O. Couvreur, P.; ChemCommun, 2010, 46, 2602.

25. Formulation of Didanosine Prodrugs into PEGylated Poly(alkyl cyanoacrylate) Nanoparticles and Uptake by Brain Endothelial Cells. Pierson, L.-A; Nicolas, J.; Lalanne, M.; Brambilla, D.; Marsaud, V.; Nicolas, V.; Ball, R.; Stanimirovic, D.; Couvreur, P.; Andrieux, K. J Nanoneurosci, 2009, 1, 174.



  • Pharmacy
  • Biomedical Engineering
  • Medical Biochemistry
  • Chemistry

Champ d’expertise

  • Biomaterials
  • Nanobiotechnologie
  • Axe : Formulation et analyse du médicament
  • Formulation de Drug Delivery Systems
  • Nanotechnologie
  • Matériaux pharmaceutiques
  • Vectorisation de gènes et de médicaments